NEUROBLASTOMA

This study tests a vaccine designed to teach the immune system to recognize and attack neuroblastoma cells. The vaccine contains two antigens (GD2L and GD3L) found on these cancer cells, plus an immune booster called OPT-821. Patients also take oral β-glucan, a yeast-derived suga…

This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. It combines specially engineered immune cells (GD2-CAR T cells) with a chickenpox vaccine to help the cells last longer in the body. The main goals…

This study tests a new treatment for children whose high-risk neuroblastoma has returned or not responded to standard therapy. It combines a tumor vaccine (to train the immune system to attack cancer cells) with daily low-dose chemotherapy (to weaken the tumor's defenses). The go…

This early-stage trial tests a new treatment called GD2 CAR T cells in 12 children and teens aged 1-16 with neuroblastoma that has come back or not responded to standard therapy. The therapy involves taking a patient's own immune cells, modifying them to better recognize and atta…

This study tests a drug called DFMO in children with high-risk neuroblastoma who are currently in remission. The goal is to see if taking DFMO for two years can stop the cancer from returning. About 441 participants will take the medicine by mouth twice a day.

This early-phase trial tests a treatment that uses a child's own natural killer (NK) cells, boosted in the lab, along with standard antibody therapy (dinutuximab) for relapsed or hard-to-treat neuroblastoma. The study aims to find the safest dose of NK cells and see if adding len…

This early-stage study tests a new drug called LY3295668 erbumine in children whose neuroblastoma has come back or not responded to treatment. The main goal is to see if the drug is safe and to find the right dose. About 71 participants will receive the drug alone or with other c…

This early-phase study tests a new treatment for children and young adults with neuroblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells. The …

This study tests a combination of two drugs—an antibody called Hu3F8 and a growth factor called GM-CSF—in children with high-risk neuroblastoma that has come back or not responded to standard therapy. The goal is to find a safe dose and see how well the body tolerates the treatme…

This study tests whether adding two chemotherapy drugs (irinotecan and temozolomide) to the standard immunotherapy regimen (dinutuximab, GM-CSF, and isotretinoin) can safely improve outcomes for children with high-risk neuroblastoma after they have completed initial intensive the…

This study tests a personalized approach for children with non-high-risk neuroblastoma, where treatment is guided by the tumor's biology and how it responds over time. Some children may only need monitoring instead of immediate therapy, potentially avoiding harsh side effects. Th…

This study tests an experimental drug, CLR 131, in children, adolescents, and young adults with certain cancers (like neuroblastoma, lymphoma, and brain tumors) that have come back or not responded to standard treatments. The main goal is to find a safe dose and see if the drug c…

This early-stage study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest and most effective d…

This early-stage study tests a combination of three drugs (radioactive therapy, an immunotherapy, and a checkpoint inhibitor) in children whose neuroblastoma has returned or not responded to standard treatment. The main goal is to see if the combination is safe and tolerable. Abo…

This early-phase study tests a three-drug combination (sorafenib, cyclophosphamide, and topotecan) in children and young adults with neuroblastoma that has come back or not responded to treatment. The main goal is to find the safest dose of sorafenib when given with the other two…

This study tested whether a fecal microbiota transplant (FMT) could help treat neuroblastoma, a type of childhood cancer, in one patient. The idea was to fix gut bacteria problems before and during standard cancer treatment. Only children with a specific gut bacteria imbalance we…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This early-stage trial tests a personalized treatment for children with recurrent neuroblastoma or a rare brainstem tumor called DIPG. The approach combines targeted drugs with the child's own immune cells, trained to attack the cancer. The main goal is to check safety and find t…

This early-phase study tests a personalized cell therapy for children and young adults (ages 1–30) with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells carrying…

This early-phase study tests a new gene therapy for children whose neuroblastoma has returned or not responded to treatment. Researchers take the patient's own immune cells, add genes to help them recognize and attack the cancer, and give them back along with chemotherapy and an …

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…

This study tests a new radioactive tracer called 18F-DA for PET scans to see if it can find neuroblastoma and pheochromocytoma tumors more clearly than the current tracer. About 20 children and adults with known or suspected tumors will receive the tracer and be monitored for sid…

This study tests a new radioactive imaging agent called 18F-mFBG to see if it can accurately find or rule out neuroblastoma, a type of childhood cancer. About 43 people with known or suspected neuroblastoma will receive the agent and have a PET scan. The goal is to see if this me…

This study involves 20 children and young adults with neuroendocrine tumors (like neuroblastoma) that have spread. Researchers are testing whether a special PET/CT scan using a radioactive tracer called 68Ga-DOTATATE can find tumors better than the standard MIBG scan. The goal is…

This study tests if a special PET scan using methionine, a natural amino acid, can help see tumors in children and young adults with brain or solid tumors. About 500 participants will get the scan to see how well it finds tumors and tells them apart from scar tissue. The goal is …

This study tests if giving the drug dinutuximab over 4 hours or less is safe and practical for children with high-risk neuroblastoma. Currently, standard infusions take 10-20 hours and require a hospital stay. The goal is to see if a shorter infusion can be used in an outpatient …

This study looks at tumor samples from children and young adults (ages 1 to 30) with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to find specific genetic changes and immune system markers that could guide future treatments. No new therapy…

This study looks for new types of gene changes that might raise cancer risk. Researchers compare cancer patients with their healthy parents and family members to find gene changes that appear only in the patient. About 1,275 people with breast, colon, germ cell, neuroblastoma, re…

This study tests a new, highly detailed PET/CT scanner (NeuroEXPLORER) against the standard scanner for people with conditions like dementia, Parkinson's, brain tumors, and head/neck cancers. About 1600 participants will get both scans in one visit to see if the new scanner gives…

This study uses a special PET scan to see how a lab-made antibody (Hu3F8) moves through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants received a radioactive version of the antibody, and blood samples and scans were taken ov…